Disease · EFO_0004229

Dupuytren Contracture

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Dupuytren Contracture. Diseases, record EFO_0004229. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0004229

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Dupuytren Contracture; Open Targets
Open Targets ID: EFO_0004229; Open Targets
Other names: Dupuytren contracture (disease), Dupuytren's Contracture, Dupuytren's Disease, palmar fibromatosis, palmar part of manus fibromatosis; Open Targets
MeSH: D004387; MeSH
Highest stage of its drugs: Approval, for 1 of its 6 drugs, from DailyMed and PMDA; Open Targets

Drugs6

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
COLLAGENASE CLOSTRIDIUM HISTOLYTICUM	CHEMBL2108709	Enzyme	Approval	DailyMed and PMDA	30	27	27	Drugs and targets
TRIAMCINOLONE ACETONIDE	CHEMBL1504	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
ADALIMUMAB	CHEMBL1201580	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
SODIUM CHLORIDE	CHEMBL1200574	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
LIDOCAINE	CHEMBL79	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
ROPIVACAINE	CHEMBL1077896	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets37

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
SCN10A	Sodium channel alpha subunit	2	Sodium channel alpha subunit blocker	Phase 1	https://conductscience.org/library/genes/6336	Drugs and targets
SCN11A	Sodium channel alpha subunit	2	Sodium channel alpha subunit blocker	Phase 1	https://conductscience.org/library/genes/11280	Drugs and targets
SCN1A	Sodium channel alpha subunit	2	Sodium channel alpha subunit blocker	Phase 1	https://conductscience.org/library/genes/6323	Drugs and targets
SCN2A	Sodium channel alpha subunit	2	Sodium channel alpha subunit blocker	Phase 1	https://conductscience.org/library/genes/6326	Drugs and targets
SCN3A	Sodium channel alpha subunit	2	Sodium channel alpha subunit blocker	Phase 1	https://conductscience.org/library/genes/6328	Drugs and targets
SCN4A	Sodium channel alpha subunit	2	Sodium channel alpha subunit blocker	Phase 1	https://conductscience.org/library/genes/6329	Drugs and targets
SCN5A	Sodium channel alpha subunit	2	Sodium channel alpha subunit blocker	Phase 1	https://conductscience.org/library/genes/6331	Drugs and targets
SCN7A	Sodium channel alpha subunit	2	Sodium channel alpha subunit blocker	Phase 1	https://conductscience.org/library/genes/6332	Drugs and targets
SCN8A	Sodium channel alpha subunit	2	Sodium channel alpha subunit blocker	Phase 1	https://conductscience.org/library/genes/6334	Drugs and targets
SCN9A	Sodium channel alpha subunit	2	Sodium channel alpha subunit blocker	Phase 1	https://conductscience.org/library/genes/6335	Drugs and targets

1 to 10 of 37

See all 37 targets

Trials30

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01674634	Safety and Efficacy of Two Concurrent Injections of AA4500 in Adult Subjects With Multiple Dupuytren's Contractures	Phase 3	715	2015-02-20	Dupuytren's Contracture	COLLAGENASE CLOSTRIDIUM HISTOLYTICUM	Its record names the disease	ClinicalTrials.gov
NCT00528606	AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Dupuytren's Contracture	Phase 3	308	2010-10-22	Dupuytren's Contracture	COLLAGENASE CLOSTRIDIUM HISTOLYTICUM	Its record names the disease	ClinicalTrials.gov
NCT00528424	AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease	Phase 3	286	2010-10-22	Advanced Dupuytren's Disease	COLLAGENASE CLOSTRIDIUM HISTOLYTICUM	Its record names the disease	ClinicalTrials.gov
NCT01229436	Treatment Of Dupuytren's Contracture With Collagenase Clostridium Histolyticum Injection (Xiapex)	Phase 3	254	2014-03-17	Dupuytren's Contracture	COLLAGENASE CLOSTRIDIUM HISTOLYTICUM	Its record names the disease	ClinicalTrials.gov
NCT00528840	Safety and Efficacy Study of AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease	Phase 3	201	2010-10-22	Advanced Dupuytren's Disease	COLLAGENASE CLOSTRIDIUM HISTOLYTICUM	Its record names the disease	ClinicalTrials.gov
NCT03180957	Repurposing Anti-TNF for Treating Dupuytren's Disease	Phase 2	140	2024-06-28	Dupuytren's Disease	ADALIMUMAB, SODIUM CHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT01588353	Collagenase Option for Reduction of Dupuytren's Contracture in Japan	Phase 3	104	2017-02-14	Dupuytren's Contracture	COLLAGENASE CLOSTRIDIUM HISTOLYTICUM	Its record names the disease	ClinicalTrials.gov
NCT02193828	Phase 2a Dose-Ranging Study to Evaluate Safety and Effectiveness of AA4500 in Treatment of Dupuytren's Disease Nodules	Phase 2	76	2015-07-07	Dupuytren's Disease	COLLAGENASE CLOSTRIDIUM HISTOLYTICUM	Its record names the disease	ClinicalTrials.gov
NCT00533273	Non-US Study of AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease	Phase 3	66	2010-10-22	Advanced Dupuytren's Disease	COLLAGENASE CLOSTRIDIUM HISTOLYTICUM	Its record names the disease	ClinicalTrials.gov
NCT01407068	Administration of Two Injections for Multiple Dupuytren's Contractures	Phase 3	60	2015-02-20	Dupuytren's Contracture	COLLAGENASE CLOSTRIDIUM HISTOLYTICUM	Its record names the disease	ClinicalTrials.gov

1 to 10 of 30

See all 30 trials

Comparisons in its trials8

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
AA4500 0.58 mg vs Placebo: serious adverse events	8 of 204	1 of 104	308	NCT00528606	Trial comparisons
Anti-TNF vs Placebo: deaths from any cause	0 of 70	0 of 70	140	NCT03180957	Trial comparisons
Anti-TNF vs Placebo: serious adverse events	0 of 70	1 of 70	140	NCT03180957	Trial comparisons
AA4500 0.58 mg vs Placebo: serious adverse events	7 of 63	1 of 21	84	NCT00533273	Trial comparisons
AA4500 vs Placebo: serious adverse events	2 of 23	1 of 15	38	NCT00260429	Trial comparisons
Collagenase Injection vs Limited Palmar Fasciectomy: deaths from any cause	0 of 8	0 of 13	21	NCT02725528	Trial comparisons
Collagenase Injection vs Limited Palmar Fasciectomy: serious adverse events	0 of 8	0 of 13	21	NCT02725528	Trial comparisons
Collagenase Injection vs Limited Palmar Fasciectomy: Recurrence Rates	3 of 7	1 of 9	16	NCT02725528	Trial comparisons

Papers from its trials13

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
40272357	RESULT	1	PubMed
38346307	RESULT	1	PubMed
36378072	RESULT	1	PubMed
35949922	RESULT	1	PubMed
30722822	RESULT	1	PubMed
29983350	RESULT	1	PubMed
27313184	RESULT	1	PubMed
41334972	DERIVED	1	PubMed
30808670	DERIVED	1	PubMed
28854973	DERIVED	1	PubMed

1 to 10 of 13

See all 13 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_0004229

GET https://conductscience.org/api/diseases/v1/EFO_0004229/targets?page=2

API reference For AI assistants